Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
Kendall Szulimowski, 2021 PharmD candidate
Advertisement
Kendall Szulimowski is a 2021 PharmD candidate at the University of Connecticut School of Pharmacy in Storrs.
Articles by Kendall Szulimowski, 2021 PharmD candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
2
Scripted for Her: The Pharmacist's Role in HPV Prevention
3
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
4
Q&A: Trust, Clinical Oversight Must Anchor Convenient Pharmacy Care
5